A biotechnology company focused on developing antibody-based therapies for autoimmune diseases and cancer. Its lead product, efgartigimod (marketed as Vyvgart), targets rare autoimmune conditions and has become a key revenue driver as the company expands into additional indications. Investors track ...
1 member of Congress has disclosed 1 trade in argenx SE (ARGX), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-07-10 | Daniel Goldman | sell | $1K – $15K |